Long COVID occurrence in COVID-19 survivors.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
11 04 2022
11 04 2022
Historique:
received:
29
12
2021
accepted:
09
03
2022
entrez:
12
4
2022
pubmed:
13
4
2022
medline:
14
4
2022
Statut:
epublish
Résumé
This cross-sectional study aimed to investigate the post-acute consequences of COVID-19. We conducted a self-administered questionnaire survey on sequelae, psychological distress (K6), impairments in work performance (WFun), and COVID-19-related experiences of stigma and discrimination in two designated COVID-19 hospitals in Hiroshima Prefecture, Japan, between August 2020 and March 2021. The prevalence of sequelae was calculated by age and COVID-19 severity. Factors independently associated with sequelae or psychological distress were identified using logistic regression analysis. Among 127 patients who had recovered from COVID-19, 52.0% had persistent symptoms at a median of 29 days [IQR 23-128] after COVID-19 onset. Among patients with mild COVID-19, 49.5% had sequelae. The most frequent symptoms were olfactory disorders (15.0%), taste disorders (14.2%), and cough (14.2%). Multivariate analysis showed that age was an independent risk factor for sequelae (adjusted odds ratios [AOR] for ≥ 60 years vs. < 40 years 3.63, p = 0.0165). Possible psychological distress was noted in 30.7% (17.9% of males and 45.0% of females). Female sex and the presence of sequelae were independent risk factors for psychological distress. Of all participants, 29.1% had possible impairments in work performance. Experiences of stigma and discrimination were reported by 43.3% of participants. This study revealed the significant impacts of Long COVID on health in local communities. A large-scale, long-term cohort study is desired.
Identifiants
pubmed: 35411017
doi: 10.1038/s41598-022-10051-z
pii: 10.1038/s41598-022-10051-z
pmc: PMC8996498
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
6039Informations de copyright
© 2022. The Author(s).
Références
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
JAMA. 2020 Aug 25;324(8):782-793
pubmed: 32648899
Lung. 2021 Apr;199(2):113-119
pubmed: 33569660
Nat Med. 2021 Sep;27(9):1607-1613
pubmed: 34163090
BJPsych Open. 2021 Feb 09;7(2):e47
pubmed: 33557964
Clin Microbiol Infect. 2021 Feb;27(2):258-263
pubmed: 33031948
Lancet. 2021 Jan 16;397(10270):220-232
pubmed: 33428867
Lancet Infect Dis. 2020 Jul;20(7):782
pubmed: 32592670
Lancet Psychiatry. 2021 Feb;8(2):130-140
pubmed: 33181098
J Med Virol. 2021 Feb;93(2):1175-1179
pubmed: 32841387
Brain Behav Immun. 2020 Oct;89:594-600
pubmed: 32738287
J Infect. 2020 Dec;81(6):e4-e6
pubmed: 32853602
Clin Microbiol Infect. 2021 Jan;27(1):89-95
pubmed: 32979574
Clin Infect Dis. 2021 Dec 6;73(11):e4058-e4063
pubmed: 33252665
Nat Med. 2021 Apr;27(4):601-615
pubmed: 33753937
PLoS One. 2020 Dec 10;15(12):e0243635
pubmed: 33301520
PLoS One. 2020 Nov 9;15(11):e0240784
pubmed: 33166287
Nat Med. 2021 Apr;27(4):626-631
pubmed: 33692530
J Med Virol. 2021 Feb;93(2):1013-1022
pubmed: 32729939
J Infect. 2021 Mar;82(3):378-383
pubmed: 33450302
Cell Mol Neurobiol. 2022 Jan;42(1):217-224
pubmed: 32840758
Acta Otolaryngol. 2020 Dec;140(12):1032-1035
pubmed: 32852240
Arch Gen Psychiatry. 2003 Feb;60(2):184-9
pubmed: 12578436
JAMA. 2020 Aug 11;324(6):603-605
pubmed: 32644129
Infect Dis (Lond). 2021 Oct;53(10):737-754
pubmed: 34024217
Ann Intern Med. 2021 Apr;174(4):576-578
pubmed: 33175566
Occup Med (Lond). 2020 Apr 20;70(2):95-100
pubmed: 32009152
J Occup Health. 2015;57(6):521-31
pubmed: 26345178
ERJ Open Res. 2021 Feb 08;7(1):
pubmed: 33575312
BMJ. 2020 Sep 7;370:m3489
pubmed: 32895219
ERJ Open Res. 2020 Oct 26;6(4):
pubmed: 33257910
Thorax. 2021 Apr;76(4):399-401
pubmed: 33273026
Crit Care. 2020 Jul 13;24(1):422
pubmed: 32660650
BMJ. 2021 Jul 26;374:n1648
pubmed: 34312178